nach oben

Erschienen in:

06.08.2019 | Trockenes Auge | Leitthema

Forschungs- und Entwicklungsbedarf in der Augenheilkunde („Unmet needs“)

Ein konsensbasierter Fahrplan des European Vision Institute (EVI) für die Jahre 2019 bis 2025

verfasst von: Univ.-Prof. C. Cursiefen, MD, PhD, F. Cordeiro, J. Cunha-Vaz, T. Wheeler-Schilling, H. P. N. Scholl, das EVI Steering Board

Erschienen in: Die Ophthalmologie | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zielsetzung

Bestimmung des Forschungs- und Entwicklungsbedarfs, der in den nächsten Jahren (2019–2025) realistischerweise angegangen werden kann, und Beschreibung möglicher Forschungswege, um diesen Herausforderungen zu begegnen.

Methoden

Die Ergebnisse eines Konsensusprozesses im European Vision Institute (EVI, Brüssel) werden zusammengefasst. Folgende Themengebiete werden behandelt: Glaukom, Netzhautdystrophien, diabetische Retinopathie, trockenes Auge, Hornhauterkrankungen, Katarakt- und refraktive Chirurgie.

Ergebnisse

Der Forschungsbedarf in den genannten Krankheitsbereichen wird erörtert, realisierbare Forschungsprojekte werden skizziert.

Schlussfolgerungen

Beträchtliche Fortschritte auf dem Gebiet der Augenheilkunde und in den für Patienten relevanten Ergebnissen sind in der nahen Zukunft möglich.

Scott AW, Bressler N, Ffolkes S, Wittenborn JS, Jorkasky J (2016) Public attitudes about eye and vision health. Jama Ophthalmol 134(10):1111–1118 (Oct)CrossRefPubMed

Kass MA, Heuer DK, Higginbotham EJ et al (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701–713 (discussion 829–730. 2002/06/07)CrossRef

Collaborative Normal-Tension Glaucoma Study Group (1998) The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126:498–505CrossRef

Weinreb RN, Kaufman PL (2011) Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function. Invest Ophthalmol Vis Sci 52:7842–7851. https://doi.org/10.1167/iovs.11-7895 CrossRefPubMedPubMedCentral

Kuang TM, Zhang C, Zangwill LM et al (2015) Estimating lead time gained by optical coherence tomography in detecting glaucoma before development of visual field defects. Ophthalmology 122:2002–2009. https://doi.org/10.1016/j.ophtha.2015.06.015 CrossRefPubMedPubMedCentral

Yu M, Lin C, Weinreb RN et al (2016) Risk of visual field progression in glaucoma patients with progressive retinal nerve fiber layer thinning: a 5‑year prospective study. Ophthalmology 123:1201–1210. https://doi.org/10.1016/j.ophtha.2016.02.017 CrossRefPubMed

Yap TE, Donna P, Almonte MT et al (2018) Real-time imaging of retinal ganglion cell apoptosis. Cells 7. https://doi.org/10.3390/cells7060060 CrossRefPubMedPubMedCentral

Rossi EA, Granger CE, Sharma R et al (2017) Imaging individual neurons in the retinal ganglion cell layer of the living eye. Proc Natl Acad Sci U S A 114:586–591. https://doi.org/10.1073/pnas.1613445114 CrossRefPubMedPubMedCentral

Jonnal RS, Kocaoglu OP, Zawadzki RJ et al (2016) A review of adaptive optics optical coherence tomography: technical advances, scientific applications, and the future. Invest Ophthalmol Vis Sci 57:OCT51–68. https://doi.org/10.1167/iovs.16-19103 CrossRefPubMedPubMedCentral

10.

De Moraes CG, Hood DC, Thenappan A et al (2017) Visual fields miss central defects shown on 10-2 tests in glaucoma suspects, ocular hypertensives, and early glaucoma. Ophthalmology 124:1449–1456. https://doi.org/10.1016/j.ophtha.2017.04.021 CrossRefPubMedPubMedCentral

11.

Kim YK, Ha A, Na KI et al (2017) Temporal relation between macular ganglion cell-inner plexiform layer loss and peripapillary retinal nerve fiber layer loss in glaucoma. Ophthalmology 124:1056–1064. https://doi.org/10.1016/j.ophtha.2017.03.014 CrossRefPubMed

12.

den Haan J, Verbraak FD, Visser PJ et al (2017) Retinal thickness in Alzheimer’s disease: a systematic review and meta-analysis. Alzheimers Dement 6:162–170. https://doi.org/10.1016/j.dadm.2016.12.014 CrossRef

13.

Yu JG, Feng YF, Xiang Y et al (2014) Retinal nerve fiber layer thickness changes in Parkinson disease: a meta-analysis. PLoS ONE 9:e85718. https://doi.org/10.1371/journal.pone.0085718 CrossRefPubMedPubMedCentral

14.

Kim JH, Caprioli J (2018) Intraocular pressure fluctuation: is it important? J Ophthalmic Vis Res 13:170–174. https://doi.org/10.4103/jovr.jovr_35_18 CrossRefPubMedPubMedCentral

15.

Tarkkanen A, Leikola J (1967) Postural variations of the intraocular pressure as measured with the Mackay-Marg tonometer. Acta Ophthalmol 45:569–575CrossRef

16.

Qureshi IA (1995) Effects of mild, moderate and severe exercise on intraocular pressure of sedentary subjects. Ann Hum Biol 22:545–553CrossRefPubMed

17.

Ittoop SM, SooHoo JR, Seibold LK et al (2016) Systematic review of current devices for 24-h intraocular pressure monitoring. Adv Ther 33:1679–1690. https://doi.org/10.1007/s12325-016-0388-4 CrossRefPubMedPubMedCentral

18.

Pillunat LE, Erb C, Junemann AG et al (2017) Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents. Clin Ophthalmol 11:1583–1600. https://doi.org/10.2147/OPTH.S135316 CrossRefPubMedPubMedCentral

19.

Resende AF, Patel NS, Waisbourd M et al (2016) iStent(R) trabecular microbypass stent: an update. J Ophthalmol 2016:1–9. https://doi.org/10.1155/2016/2731856 CrossRef

20.

Vold SA II, Craven ER et al (2016) Two-year COMPASS trial results: supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts. Ophthalmology 123:2103–2112. https://doi.org/10.1016/j.ophtha.2016.06.032 CrossRefPubMed

21.

Scholl HP, Strauss RW, Singh MS, Dalkara D, Roska B, Picaud S, Sahel JA (2016) Emerging therapies for inherited retinal degeneration. Sci Transl Med 8(368):368rv6CrossRefPubMed

22.

Liew G, Michaelides M, Bunce C (2014) A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 4:e4015CrossRefPubMedPubMedCentral

23.

Duncan et al (2016) Recommendations on clinical assessment of patients with inherited retinal degenerations—2016. https://www.aao.org/clinical-statement/recommendations-on-clinical-assessment-of-patients#Authors. Zugegriffen: 17. Nov. 2018

24.

Roska B, Sahel JA (2018) Restoring vision. Nature 557(7705):359–367CrossRefPubMed

25.

RetNet. https://sph.uth.edu/retnet/. Zugegriffen: 26. Apr. 2019

26.

Consugar MB, Navarro-Gomez D, Place EM, Bujakowska KM, Sousa ME, Fonseca-Kelly ZD, Taub DG, Janessian M, Wang DY, Au ED, Sims KB, Sweetser DA, Fulton AB, Liu Q, Wiggs JL, Gai X, Pierce EA (2015) Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible, and more sensitive for variant detection, than exome sequencing. Genet Med 17(4):253–261CrossRefPubMed

27.

Duncan JL, Pierce EA, Laster AM, Daiger SP, Birch DG, Ash JD, Iannaccone A, Flannery JG, Sahel JA, Zack DJ, Zarbin MA, The Foundation Fighting Blindness Scientific Advisory Board (2018) Inherited retinal degenerations: current landscape and knowledge gaps. Transl Vis Sci Technol 7(4):6CrossRefPubMedPubMedCentral

28.

Russell S et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390(10097):849–860CrossRefPubMedPubMedCentral

29.

Azeredo da Silveira R, Roska B (2011) Cell types, circuits, computation. Curr Opin Neurobiol 21:664–671CrossRefPubMed

30.

Juettner et al (2018) Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates, and humans. bioRxiv 2018. https://www.biorxiv.org/content/10.1101/434720v1. Zugriff 27.6.2019.

31.

Strauss RW, Ho A, Muñoz B, Cideciyan AV, Sahel JA, Sunness JS, Birch DG, Bernstein PS, Michaelides M, Traboulsi EI, Zrenner E, Sadda S, Ervin AM, West S, Scholl HP, Progression of Stargardt Disease Study Group. (2016) The natural history of the progression of atrophy secondary to Stargardt disease (Progstar) studies: design and baseline characteristics: progstar report no. 1. Ophthalmology 123(4):817–828CrossRefPubMed

32.

Kong X, Fujinami K, Strauss RW, Munoz B, West SK, Cideciyan AV, Michaelides M, Ahmed M, Ervin AM, Schönbach E, Cheetham JK, Scholl HPN (2018) ProgStar study group visual acuity change over 24 months and its association with foveal phenotype and genotype in individuals with Stargardt disease: ProgStar study report no. 10. Jama Ophthalmol 136(8):920–928CrossRefPubMedPubMedCentral

33.

International Diabetes Federeation (Hrsg) (2013) IDF Diabetes Atlas, sixth. Aufl. International Diabetes Federation, Brussels (Available from: www.idf.org/diabetesatlas)

34.

Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117(6):609–614CrossRef

35.

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4):615–625CrossRefPubMed

36.

The Diabetic Retinopathy Clinical Research Network (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203CrossRefPubMedCentral

37.

Figueira J, Silva R, Henriques J, Caldeira RP, Laíns I, Melo P et al (2016) Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial. Ophthalmologica 235(1):34–41CrossRefPubMed

38.

Cunha-Vaz J, Bernardes R (2005) Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. Prog Retin Eye Res 24(3):355–377CrossRefPubMed

39.

Nunes S, Ribeiro L, Lobo C, Cunha-Vaz J (2013) Three different phenotypes of mild Nonproliferative diabetic retinopathy with different risks for development of clinically significant macular edema. Invest Ophthalmol Vis Sci 54(7):4595–4604CrossRefPubMed

40.

Ribeiro ML, Nunes SG, Cunha-Vaz JG (2013) Microaneurysm turnover at the macula predicts risk of development of clinically significant macular edema in persons with mild nonproliferative diabetic retinopathy. Diabetes Care 36(5):1254–1259CrossRefPubMedPubMedCentral

41.

Cunha-Vaz J, Ribeiro L, Lobo C (2014) Phenotypes and biomarkers of diabetic retinopathy. Prog Retin Eye Res 41:90–111CrossRefPubMed

42.

Marques IP, Alves D, Santos T, Mendes L, Santos AR, Lobo C et al (2018) Multimodal imaging of the initial stages of diabetic retinopathy. Different disease pathways in different patients. Diabetes 6:db181077

43.

Cunha-Vaz J, Santos T, Ribeiro L, Alves D, Marques I, OCT-leakage GM (2016) A new method to identify and locate abnormal fluid accumulation in diabetic retinal edema. Invest Ophthalmol Vis Sci 57(15):6776–6783CrossRefPubMed

44.

Cunha-Vaz J, Santos T, Alves D, Marques I, Neves C, Soares M et al (2017) Agreement between OCT leakage and fluorescein angiography to identify sites of alteration of the blood–retinal barrier in diabetes. Ophthalmol Retina 1(5):395–403CrossRefPubMed

45.

Santos AR, Alves D, Santos T, Figueira J, Silva R, Cunha-Vaz JG (2019) Measurements of retinal fluid by OCT leakage in diabetic macular edema: a biomarker of visual acuity response to treatment. Retina 39(1):52–60CrossRefPubMed

46.

Santos AR, Ribeiro L, Bandello F, Lattanzio R, Egan C, Frydkjaer-Olsen U et al (2017) Functional and structural findings of neurodegeneration in early stages of diabetic retinopathy: cross-sectional analyses of baseline data of the EUROCONDOR project. Diabetes 66(9):2503–2510CrossRefPubMed

47.

Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y et al (2009) Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE 4(12):e8158CrossRefPubMedPubMedCentral

48.

Srividya G, Jain M, Mahalakshmi K, Gayathri S, Raman R, Angayarkanni N (2018) A novel and less invasive technique to assess cytokine profile of vitreous in patients of diabetic macular oedema. Eye 32(4):820–829CrossRefPubMedPubMedCentral

49.

Oh IK, Kim SW, Oh J, Lee TS, Huh K (2010) Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res 35(12):1116–1127CrossRefPubMed

50.

Lee WJ, Kang MH, Seong M, Cho HY (2012) Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol 96(11):1426–1430CrossRefPubMed

51.

Dong N, Xu B, Wang B, Chu L (2013) Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis 19:1734–1746PubMedPubMedCentral

52.

Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, de Paiva CS, Gomes JAP, Hammitt KM, Jones L, Nichols JJ, Nichols KK, Novack GD, Stapleton FJ, Willcox MDP, Wolffsohn JS, Sullivan DA (2017) TFOS DEWS II report executive summary. Ocul Surf 15(4):802–812CrossRefPubMed

53.

Matthaei M, Sandhaeger H, Hermel M, Adler W, Jun AS, Cursiefen C, Heindl LM (2017) Changing indications in penetrating keratoplasty: a systematic review of 34 years of global reporting. Transplantation 101(6):1387–1399CrossRefPubMed

54.

Hos D, Matthaei M, Bock F, Maruyama K, Notara M, Clahsen T, Hou Y, Le VNH, Salabarria AC, Horstmann J, Bachmann BO, Cursiefen C (2019) Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation. Prog Retin Eye Res. https://doi.org/10.1016/j.preteyeres.2019.07.001 CrossRefPubMed

55.

Hos D, Tuac O, Schaub F, Stanzel TP, Schrittenlocher S, Hellmich M, Bachmann BO, Cursiefen C (2017) Incidence and clinical course of immune reactions after descemet membrane endothelial keratoplasty: retrospective analysis of 1000 consecutive eyes. Ophthalmology 124(4):512–518CrossRefPubMed

56.

Bock F, Maruyama K, Regenfuss B, Hos D, Steven P, Heindl LM, Cursiefen C (2013) Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res 34:89–124CrossRefPubMed

57.

Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, Zahn G, Wiegand S, Chen L, Cursiefen C (2010) Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 184(2):535–539CrossRefPubMed

58.

Cursiefen C, Colin J, Dana R, Diaz-Llopis M, Faraj LA, Garcia-Delpech S, Geerling G, Price FW, Remeijer L, Rouse BT, Seitz B, Udaondo P, Meller D, Dua H (2012) Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 96(1):3–9CrossRefPubMed

59.

Cursiefen C, Viaud E, Bock F, Geudelin B, Ferry A, Kadlecová P, Lévy M, Al Mahmood S, Colin S, Thorin E, Majo F, Frueh B, Wilhelm F, Meyer-Ter-Vehn T, Geerling G, Böhringer D, Reinhard T, Meller D, Pleyer U, Bachmann B, Seitz B (2014) Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I‑CAN study. Ophthalmology 121(9):1683–1692CrossRefPubMed

60.

Weiss JS, Møller HU, Aldave AJ, Seitz B, Bredrup C, Kivelä T, Munier FL, Rapuano CJ, Nischal KK, Kim EK, Sutphin J, Busin M, Labbé A, Kenyon KR, Kinoshita S, Lisch W (2015) IC3D classification of corneal dystrophies—edition 2. Cornea 34(2):117–159CrossRefPubMed

61.

Hos D, van Essen TH, Bock F, Chou CH, Pan HA, Lin CC, Huang MC, Chen SC, Cursiefen C, Jager MJ (2014) Decellularized collagen matrix from tilapia fish scales for corneal reconstruction (BioCornea). Ophthalmologe 111(11):1027–1032. https://doi.org/10.1007/s00347-013-3011-y (Article in German)CrossRefPubMed

62.

Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, Mantelli F, REPARO Study Group (2018) Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 125(9):1332–1343CrossRefPubMed

63.

Hos D, Bukowiecki A, Horstmann J, Bock F, Bucher F, Heindl LM, Siebelmann S, Steven P, Dana R, Eming SA, Cursiefen C (2017) Transient ingrowth of lymphatic vessels into the physiologically avascular cornea regulates corneal edema and transparency. Sci Rep 7(1):7227–7223CrossRefPubMedPubMedCentral

64.

Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G (2010) Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 363(2):147–155CrossRefPubMed

65.

Notara M, Lentzsch A, Coroneo M, Cursiefen C (2018) The role of limbal epithelial stem cells in regulating corneal (lymph)angiogenic privilege and the micromilieu of the limbal niche following UV exposure. Stem Cells Int 2018:1–15CrossRef

66.

Notara M, Behboudifard S, Kluth MA, Maßlo C, Ganss C, Frank MH, Schumacher B, Cursiefen C (2018) UV light-blocking contact lenses protect against short-term UVB-induced limbal stem cell niche damage and inflammation. Sci Rep 8(1):12564CrossRefPubMedPubMedCentral

67.

Schlereth SL, Iden S, Mescher M, Ksander BR, Bosch JJ, Cursiefen C, Heindl LM (2015) A novel model of metastatic conjunctival melanoma in immune-competent mice. Invest Ophthalmol Vis Sci 56(10):5965–5973CrossRefPubMed

68.

Siebelmann S, Horstmann J, Scholz P, Bachmann B, Matthaei M, Hermann M, Cursiefen C (2018) Intraoperative changes in corneal structure during excimer laser phototherapeutic keratectomy (PTK) assessed by intraoperative optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 256(3):575–581CrossRefPubMed

Titel: Forschungs- und Entwicklungsbedarf in der Augenheilkunde („Unmet needs“)
Ein konsensbasierter Fahrplan des European Vision Institute (EVI) für die Jahre 2019 bis 2025
verfasst von: Univ.-Prof. C. Cursiefen, MD, PhD
F. Cordeiro
J. Cunha-Vaz
T. Wheeler-Schilling
H. P. N. Scholl
das EVI Steering Board
Publikationsdatum: 06.08.2019
Verlag: Springer Medizin
Schlagwörter: Trockenes Auge
Glaukom
Refraktive Chirurgie
Diabetische Retinopathie
Diabetische Retinopathie
Erschienen in: Die Ophthalmologie / Ausgabe 9/2019
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-019-00947-z

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Forschungs- und Entwicklungsbedarf in der Augenheilkunde („Unmet needs“)

Ein konsensbasierter Fahrplan des European Vision Institute (EVI) für die Jahre 2019 bis 2025

Zusammenfassung

Zielsetzung

Methoden

Ergebnisse

Schlussfolgerungen

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Zielsetzung

Methoden

Ergebnisse

Schlussfolgerungen

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Augenbeteiligung bei Großgefäßvaskulitis erkennen und angemessen therapieren

Hornhautdystrophien in der optischen Kohärenztomographie

Kombiniertes XEN-Baerveldt-Implantat – Prinzip und Management von Komplikationen

Die Nutzung von Sonnenbrillen in Freizeit und Beruf

Hat der Mikropulslaser bei chronischer CCS einen Effekt?

Spät auftretender Enophthalmus bei persistierendem Druckschmerz

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde